FOS and Parkinson disease: In conclusion, for the first time, our study demonstrated that NONRATT023402.2 impaired rno-miR-3065-5p activity through sequestration, thereby upregulating NGFR expression, and further activating the downstream PI3K/Akt signaling pathway and c-Fos protein, which aggravated the AIMs of PD rats treated with L-DOPA.